Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Operating Leases (2019 - 2025)

Historic Operating Leases for RedHill Biopharma (RDHL) over the last 6 years, with Q4 2024 value amounting to $3000.0.

  • RedHill Biopharma's Operating Leases fell 9934.07% to $3000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $3000.0, marking a year-over-year decrease of 9934.07%. This contributed to the annual value of $3000.0 for FY2024, which is 9934.07% down from last year.
  • Latest data reveals that RedHill Biopharma reported Operating Leases of $3000.0 as of Q4 2024, which was down 9934.07% from $455000.0 recorded in Q4 2023.
  • Over the past 5 years, RedHill Biopharma's Operating Leases peaked at $6.4 million during Q4 2022, and registered a low of $3000.0 during Q4 2024.
  • Moreover, its 5-year median value for Operating Leases was $2.6 million (2021), whereas its average is $2.7 million.
  • As far as peak fluctuations go, RedHill Biopharma's Operating Leases surged by 15031.08% in 2022, and later tumbled by 9934.07% in 2024.
  • Quarter analysis of 5 years shows RedHill Biopharma's Operating Leases stood at $3.8 million in 2020, then plummeted by 32.39% to $2.6 million in 2021, then surged by 150.31% to $6.4 million in 2022, then crashed by 92.94% to $455000.0 in 2023, then tumbled by 99.34% to $3000.0 in 2024.
  • Its Operating Leases stands at $3000.0 for Q4 2024, versus $455000.0 for Q4 2023 and $6.4 million for Q4 2022.